{"a":[{"_":"FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer","$":{"href":"/pharma/fda-approves-astrazeneca-etcamah-opening-ctdna-guided-treatment-shift-breast-cancer","hreflang":"en"}}]}
RegulatoryapprovedEtcamahPositive
AI Analysis
Summary
The FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) for ctDNA-guided breast cancer treatment, marking a rare divergence from its expert advisory panel and opening a new paradigm for molecular-guided cancer care.
Outcome Details
FDA granted accelerated approval for camizestrant (Etcamah) for ctDNA-guided treatment in breast cancer
Importance:9/10
Sentiment:
0.95
FDA approvalaccelerated approvalbreast cancerctDNAmolecular-guided therapyregulatory divergence
Related Companies
Read the original article
Published by FierceBiotech on September 8, 2026 9:57 AM